On November 7, we held the 1st SafeMeds Hellas Forum on Antidepressant Withdrawal in Greece, bringing together distinguished scientists, healthcare professionals, and people with lived experience.
📊 More than 6,500 page views and 365 registrations!
My deepest gratitude to @markhoro for his invaluable scientific contribution, trust, and generous support of this initiative.
Sincere thanks to all our speakers, moderators, and participants for contributing to this important dialogue on antidepressant withdrawal, patient safety, and safer clinical practices.
#SafeMedsHellas #AntidepressantWithdrawal #MarkHorowitz #Deprescribing #PatientSafety
Please join us in supporting SafeMeds Hellas @aws_greece, a newly formed Greek organization dedicated to psychiatric medication withdrawal advocacy and awareness!
SafeMeds Hellas will host its inaugural forum on Saturday, November 7, 8:30 AM ET / 7:30 AM CT / 6:30 AM MT / 5:30 AM PT (3:30 PM Greece time), featuring Dr. Mark Horowitz as the keynote speaker. ACE founder Morgan Stewart will also be featured in a prerecorded talk.
Additional details are below, and the registration link can be found in the comments!
SafeMeds Hellas 1st Forum: Withdrawal Syndrome During Antidepressant Reduction/Discontinuation
We are very happy to invite you to the 1st Forum of SafeMeds Hellas, a free online event on withdrawal syndrome during antidepressant reduction and discontinuation. The Forum brings together scientific research, clinical practice and the voices of people with lived experience.
Our keynote speaker is Dr. Mark Horowitz @markhoro. All talks will be pre-recorded and made available a few days before the Forum, so you can watch them in advance and at your own pace. On Saturday, we will hold the panel discussions.
@: Saturday November 7 2026, 8:30 AM ET / 7:30 AM CT / 6:30 AM MT / 5:30 AM PT (3:30 PM Greece time)
Format: online
Cost: free to attend
Language: all content will be subtitled
This is the first Forum we have organised, and your support would mean a great deal to us. Please register and share it with anyone who might be interested.
💊 Μια ανεπιθύμητη ενέργεια δεν πρέπει να περνά απαρατήρητη!
Ξεκινά η #MedSafetyWeek 2026!
Ενημερωνόμαστε. Αναγνωρίζουμε. Αναφέρουμε.
Γιατί κάθε αναφορά μπορεί να συμβάλει στην ασφαλέστερη χρήση των φαρμάκων. 💚
Antidepressant withdrawal deserves greater awareness and meaningful public discussion in Greece.
With the 1st SafeMeds Hellas Forum, we are taking an important first step.
Although this initiative is based in Greece, we warmly invite our international community to be part of it.
Your experience, knowledge and support matter to us!
What questions do you believe should be addressed? What would you like healthcare professionals to better understand?
Help us bring international knowledge, clinical expertise and lived experience into this conversation in Greece.
Share your questions, spread the word and support this initiative!
📅 November 7 | Online
🌍 Greek and English subtitles
🎟️ Advance registration is required, but participation is completely FREE and open to everyone!
🔗 https://t.co/U5YNFJCqLO
#SafeMedsHellas #AntidepressantWithdrawal
🔬 SafeMeds Hellas at the Science Festival!
Proud of our dedicated volunteer scientists, whose passion, expertise, and commitment bring our mission to life!
Together, we’re bridging science and the public, promoting health literacy and patient safety.
💙 Science with purpose. Knowledge for everyone.
#SafeMedsHellas #ScienceFestival #PatientSafety
Speaking to a packed room of students at @iGEM_Patras on “Antidepressants in Cancer Care: Therapeutic Challenges, Safety, and Pharmacovigilance”.
Key highlights:
• Beyond mood: Assessing how effective they really are across indications (pain, hot flashes) & the distinct safety profile of each
• Polypharmacy risks: Managing CYP2D6 interactions (e.g., tamoxifen) and QT prolongation
• Safe tapering & barriers: Overcoming resistance to recognizing withdrawal, separating dependence from addiction or relapse, and navigating tapering obstacles
• Active reporting: Empowering patients and utilizing Yellow Card reporting
Inspiring to see the next generation of scientists prioritizing patient safety! 🔬
#Pharmacovigilance #PatientSafety #Oncology #iGEMPatras
The 1st SafeMeds Hellas Forum will bring together research, clinical practice and patient experiences to discuss antidepressant withdrawal during dose reduction or discontinuation.
🗓 7 November 2026 | 15:30 Greece time | Online
Registration details coming soon.
Great science starts with great people. 💊
We’re delighted to welcome Professor Athanasios Metaxas to SafeMeds Hellas as Scientific Advisor.
A new collaboration, driven by science and a shared commitment to safer medicines. 💚💙
#SafeMedsHellas#DrugSafety#Pharmacovigilance
We are grateful to welcome Dr Mark Horowitz as Scientific Advisor to SafeMeds Hellas.
A leading voice in safe psychiatric drug deprescribing, Dr Horowitz brings invaluable expertise to our mission of promoting safer, evidence-based medication use.
I am Dr Panagiota Kasioumi and
Through SafeMeds Hellas, my goal is to bring scientific knowledge and lived experience closer together, with patient safety and empowerment at the heart of this mission.
#SafeMedsHellas#Pharmacovigilance#MedicationSafety#PatientSafety
Behind every safer medication practice, there are people who turn knowledge into action. 💊🔬
Meet Dr Eleni Tsaousi, Scientific Associate at SafeMeds Hellas — because medication safety starts with science and grows through education.
#MedicationSafety#PatientSafety
🩺 Meet Dr Alexandros Eleftheriou, MD, BSc in Biomedical Sciences, Scientific Associate at SafeMeds Hellas, bringing medical expertise and a strong commitment to medication and patient safety.
#SafeMedsHellas#MeetOurTeam#MedicationSafety#PatientSafety
💙 Meet Eirini Chondrou, Pharmacist and SafeMeds Hellas scientific assiciate, with a special interest in medication safety and pharmacovigilance.
🔬 Knowledge empowers health.
#SafeMedsHellas#DrugSafety#Pharmacovigilance
Medication safety knows no borders. 🌍 Thank you to everyone following and supporting SafeMeds Hellas around the world. 💚
#MedicationSafety#Pharmacovigilance
We are launching Greece’s first awareness campaign on antidepressant withdrawal syndrome. If you’ve experienced withdrawal and would like to share your story (anonymously or openly), we’d love to hear from you. Help us raise awareness and give patients a voice. 💙
Delighted to have participated in the awareness event “Knowledge Means Safety – Taking Care of Our Health,” organized by the Social Support Office of the Municipality of Dropoli & Pogoni with SafeMeds HELLAS.
Happy to be invited by the Municipality of Dropull in Albania to speak about medication safety and patient protection.
We will discuss safe medicine use, adverse effects, withdrawal symptoms, and the importance of informed healthcare decisions.
An analysis of the WHO adverse effects reporting database finds that antidepressants (and SSRIs in particular) have a higher risk of withdrawal effects than buprenorphine (an opioid that is a partial agonist). Paper link below. Buprenorphine is not heroin but I think people have greatly under-estimated the risks of withdrawal of these drugs for a variety of reasons relating to the 'clinician's illusion'. Makes discussion very difficult with clinicians.
Let’s not forget the people taking antidepressants not for depression, but for chronic pain, migraines, or IBS. They’re thousands and often invisible in the conversation about withdrawal.